These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 28566230

  • 1. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO, Jasnot JY, Le Gros V, Decuypère L, Cao W, Devouassoux G.
    Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 5. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, Lim SY, Shim JJ, Lee YC, Kim YS, Oh YM, Kim S, Yoo CG.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr; 12():1589-1596. PubMed ID: 28615931
    [Abstract] [Full Text] [Related]

  • 6. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B.
    Respir Med; 2012 Dec; 106(12):1715-21. PubMed ID: 23040786
    [Abstract] [Full Text] [Related]

  • 7. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
    Kerstjens HA, Deslée G, Dahl R, Donohue JF, Young D, Lawrence D, Kornmann O.
    Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
    Huisman EL, Cockle SM, Ismaila AS, Karabis A, Punekar YS.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun; 10():1863-81. PubMed ID: 26392761
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
    Cope S, Zhang J, Williams J, Jansen JP.
    BMC Pulm Med; 2012 Jun 25; 12():29. PubMed ID: 22732017
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.
    Lung; 2013 Apr 25; 191(2):135-46. PubMed ID: 23306410
    [Abstract] [Full Text] [Related]

  • 11. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
    Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ.
    Cochrane Database Syst Rev; 2015 Jan 10; 1(1):CD010139. PubMed ID: 25575340
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.
    Int J Chron Obstruct Pulmon Dis; 2014 Jan 10; 9():215-28. PubMed ID: 24596459
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
    Mahler DA, Buhl R, Lawrence D, McBryan D.
    Pulm Pharmacol Ther; 2013 Jun 10; 26(3):348-55. PubMed ID: 23434446
    [Abstract] [Full Text] [Related]

  • 14. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW, Mahler DA, Gale R, Owen R, Kramer B.
    Respir Med; 2011 Jun 10; 105(6):892-9. PubMed ID: 21397482
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.
    Value Health; 2012 May 10; 15(3):524-33. PubMed ID: 22583463
    [Abstract] [Full Text] [Related]

  • 16. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 17. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 15; 14():249-260. PubMed ID: 30718952
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun 15; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 19. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
    Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun 15; 11():3189-3197. PubMed ID: 28008244
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.
    Respir Med; 2017 May 15; 126():105-115. PubMed ID: 28427541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.